Brief: Impedimed Says AstraZeneca Further Extends Clinical Trial Contract

ImpediMed

09/11/2022 01:32

Nov 9 (Reuters) - ImpediMed Ltd  IPD.AX :
    * ASTRAZENECA FURTHER EXTENDS CLINICAL TRIAL CONTRACT
    * ASTRAZENECA FURTHER EXTENDS CLINICAL TRIAL CONTRACT
    * EXTENSION OF TRIAL WILL GENERATE OVER A$1.0 MILLION OF
ADDITIONAL REVENUE FOR REMAINDER OF 2023 FINANCIAL YEAR
    * IN TOTAL, OVER A$6.7 MILLION IN CONTRACT VALUE HAS BEEN
SIGNED
UNDER VARIOUS ASTRAZENECA TRIAL AGREEMENTS

Source text for Eikon:  ID:nASX19Gq9m 
Further company coverage:  IPD.AX 
 ((Reuters.Briefs@thomsonreuters.com;))